Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
The Journal of Infectious Diseases
|
September 19, 2014
Human polyomavirus 7-associated pruritic rash and viremia in transplant recipients
Jonhan Ho, Jaroslaw J Jedrych, Huichen Feng, et al.
International Journal of Cancer
|
June 6, 2009
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors
Masahiro Shuda, Reety Arora, Hyun Jin Kwun, et al.
Frontiers in Oncology
|
June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Cancer Chemotherapy and Pharmacology
|
August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Tanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A Jacobs, James J Lee, Thomas J George, et al.
The Journal of Clinical Investigation
|
June 4, 2013
Multicolor microRNA FISH effectively differentiates tumor types
Neil Renwick, Pavol Cekan, Paul A Masry, et al.
Breast Cancer Research : BCR
|
December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancer
Samuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR
|
January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A Jacobs, André Robidoux, Jame Abraham, et al.
Nature Cancer
|
June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacy
Dong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
The Journal of Infectious Diseases
|
September 19, 2014
Human polyomavirus 7-associated pruritic rash and viremia in transplant recipients
Jonhan Ho, Jaroslaw J Jedrych, Huichen Feng, et al.
International Journal of Cancer
|
June 6, 2009
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors
Masahiro Shuda, Reety Arora, Hyun Jin Kwun, et al.
Frontiers in Oncology
|
June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Cancer Chemotherapy and Pharmacology
|
August 9, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Tanner J Freeman, Thomas J George, Samuel A Jacobs, et al.
Breast Cancer Research : BCR
|
April 22, 2024
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Samuel A Jacobs, Ying Wang, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A Jacobs, James J Lee, Thomas J George, et al.
The Journal of Clinical Investigation
|
June 4, 2013
Multicolor microRNA FISH effectively differentiates tumor types
Neil Renwick, Pavol Cekan, Paul A Masry, et al.
Breast Cancer Research : BCR
|
December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancer
Samuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR
|
January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A Jacobs, André Robidoux, Jame Abraham, et al.
Nature Cancer
|
June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacy
Dong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Page
of 3